{"disease":{"id":"central-nervous-system-tumor-pediatric","name":"central nervous system tumor pediatric"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05672043","title":"Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT03434262","title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT06363201","title":"Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT03638167","title":"EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Seattle Children's Hospital","has_results":false},{"nct_id":"NCT03500991","title":"HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Seattle Children's Hospital","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}